EGFR inhibition by monoclonal antibodies or small-molecule tyrosine kinase inhibitors (TKIs) has been approved for the treatment of tumor entities such as RAS wildtype colorectal cancers, squamous cell carcinoma of the head and neck (HNSCC), and EGFR mutated non-small-cell lung cancer (NSCLC) [11]. This evidence concerns the gene EGFR and colorectal cancer.